Abstract

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study
...
Blood | VOL. 132
, et. al. ...
29 Nov 2018
Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial
...
Blood | VOL. 132
, et. al. ...
29 Nov 2018
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Anthony R Mato ...
Blood | VOL. 134
Anthony R Mato, et. al.Anthony R Mato ...
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Magisetty J, Kondreddy V, Keshava S, et al. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice. Blood. 2022;139(18):2830-2841.
-
Blood | VOL. 144
--
01 Aug 2024
Human herpesvirus 6 and CAR T-cell toxicity
Karl S Peggs
Blood | VOL. 144
Karl S PeggsKarl S Peggs
01 Aug 2024
EPCR shedding light on sickle nephropathy
Erica M Sparkenbaugh
Blood | VOL. 144
Erica M SparkenbaughErica M Sparkenbaugh
01 Aug 2024
Plasma cells’ fate: it is a complex “orchestra”
Paola Neri
Blood | VOL. 144
Paola NeriPaola Neri
01 Aug 2024
View more papers